Chemical Biological Medical Systems (CBMS)
The Chemical Biological Medical Systems (CBMS) Joint Project Management Office is responsible for research, development, acquisition, fielding, and life cycle management of U.S. Food and Drug Administration (FDA)-approved medical systems for protection, treatment, and diagnostic capabilities against chemical, biological, radiological, and nuclear (CBRN) threat agents. All CBRN medical countermeasures are approved by and regulated through the FDA. The CBMS continues to aggressively explore opportunities to partner with other government agencies, industry, academia, and allied countries for all CBRN medical countermeasure efforts.
The CBMS product portfolio includes products spanning the entire acquisition life cycle. The CBMS comprises a headquarters and three supporting Joint Product Management Offices: 1) The Joint Vaccine Acquisition Program (JVAP), 2) the Medical Identification and Treatment Systems (MITS), and 3) Biosurveillance (BSV-Provisional).
Our Mission is to deliver safe, effective, and robust medical products that protect U.S. forces against validated CBRN threats. We apply government and industry best practices to develop or acquire FDA-approved products within rigorously managed cost, schedule, and performance constraints.
Our Vision is a U.S. military force that is fully sustained to fight and win in any CBRN battlespace worldwide.
Last updated: 4/22/2014 1:58:12 PM